Journal of Clinical Immunology

, Volume 29, Issue 5, pp 620–628

Interleukin 18 Promoter Variants (−137G>C and −607C>A) in Patients with Chronic Hepatitis C: Association with Treatment Response

Authors

  • Stephan L. Haas
    • Department of Medicine II, Medical Faculty at MannheimUniversity of Heidelberg
  • Christel Weiß
    • Department of Biostatistics, Medical Faculty at MannheimUniversity of Heidelberg
  • Peter Bugert
    • Institute for Transfusion Medicine and Immunology, Medical Faculty at MannheimUniversity of Heidelberg
  • Jutta Gundt
    • Department of Medicine II, Medical Faculty at MannheimUniversity of Heidelberg
  • Heiko Witt
    • Department of Hepatology and GastroenterologyCampus Virchow-Klinikum, Charité
  • Manfred V. Singer
    • Department of Medicine II, Medical Faculty at MannheimUniversity of Heidelberg
  • Thomas Berg
    • Department of Hepatology and GastroenterologyCampus Virchow-Klinikum, Charité
    • Department of Medicine II, Medical Faculty at MannheimUniversity of Heidelberg
Article

DOI: 10.1007/s10875-009-9302-z

Cite this article as:
Haas, S.L., Weiß, C., Bugert, P. et al. J Clin Immunol (2009) 29: 620. doi:10.1007/s10875-009-9302-z

Abstract

Background

Recently, two functional IL18 promoter variants, −607C>A (rs1946518) and −137G>C (rs187238), were associated with viral clearance in patients with hepatitis C. The present study focused on their relevance for treatment response.

Methods

Seven hundred fifty-seven chronically infected European patients and 791 controls were enrolled in the study. IL18 genotyping was performed by allele-specific PCR. Liver histology was available in 67.9%.

Results

Genotype and allele frequencies were equally distributed in patients and controls. No significant association with various disease characteristics was observed. However, when comparing patients with sustained virological response (SR) and non-SR, statistically significant associations were found for both variants (p = 0.0416 and p = 0.0274, respectively). In viral genotype 1, the −607A allele was positively associated with treatment response (p = 0.0190; OR 1.537; 95% CI, 1.072–2.205) and the −137G allele with a higher rate of nonresponse (p = 0.0302; OR 1.524; 95% CI, 1.040–2.233).

Conclusions

The association of IL18 variants with treatment response in genotype 1 hepatitis C patients implies a predictive and modifying role of these genetic variants.

Keywords

Hepatitis Cantiviral therapytreatment outcomegenetic alterationsinterleukin 18

Copyright information

© Springer Science+Business Media, LLC 2009